Interview with Jan Slob, President, Akrikhin
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
Address: 52, bld 5, Kosmodamianskaya Naberezhnaya,Moscow, Russia, 115054,Russia
Tel: + 7 (495) 721 36 97
AKRIKHIN founded in 1936, is one of the leading Russian pharmaceutical producer of high-quality medicines on the Russian pharmaceutical market. By 2010 results AKRIKHIN is the 5th largest local producer by revenue and production volume on the Russian pharmaceutical market.
AKRIKHIN product portfolio counts more than 150 products focused within strategically selected Anatomo Therapeutic Classes including cardiovascular, neurology, dermatology, gynecology, pediatrics. AKRIKHIN produces a wide range of socially important medications thus making a tangible input into the development of the Russian healthcare system. AKRIKHIN is a major Russian producer of Essential Drugs which account up to 70% share of the Company product portfolio. Special emphasis is made on strategic directions of high social value – production of drugs for diabetes and tuberculosis treatment.
With the Company Field Force operating in 76 cities all across Russia and highly professional marketing team AKRIKHIN has succeeded in forming a wide and well-diversified product portfolio well recognized by doctors.
AKRIKHIN production facilities is a consolidated GMP-oriented complex located 30 km from Moscow with the workshops for production of a vast spectre of drug forms: tablets, capsules, ointments, gels, creams, syrups, etc. AKRIKHIN production existing capacities amount to more than 50 mln packs per year.
Starting from 2007 AKRIKHIN entered a strategic alliance with Polpharma – the largest Polish manufacturer of generic drugs and pharmaceutical substances. AKRIKHIN and Polpharma strategic partnership embracesincorporates common product portfolio, production technologies transfer, R&D cooperation, access to best European practices and standards, joint educational programmes for personnel.
In the “Rating of influence of Russian pharmaceutical market participants” based on pharmaceutical market experts’ opinions “AKRIKHIN” is included into the TOP 3 most authoritative and influential Russian pharmaceutical producers upon the results of 2010.
AKRIKHIN priding on its 75-years’ history and traditions builds on its successful performance on the Russian pharmaceutical market, dynamically adapting itself to modern business practices and technologies.
In its portfolio of more than 150 products of various dosage forms: tablets, capsules, creams, suppositories, creams, syrups. Akrihin focuses on therapeutic areas with high social importance, ie most sought-after Russian health care system: cardiology, diabetes, neurology, dermatology, tuberculosis, gynecology and pediatrics
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
You founded Euroservice, and have managed this business since its inception in 1996. What are the key drivers that have facilitated the growth of this company from a staff of…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
PAREXEL prides itself on improving the time schedule of a product launch. What is the significance of time-to-market in the healthcare industry, and how can PAREXEL expedite the process better…
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You worked for ten years at Schering-Plough—one of the largest pharmaceutical companies in the world. In February of last year, you joined Merz Pharma, a much smaller player. Some may…
You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history…
Russia and India have recently held a number of discussions regarding increased cooperation within the pharmaceutical sector. For example, the two nation’s health ministers have discussed decreasing administrative barriers to…
Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have…
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
After a long history in Philips, this is your first tenure as a regional CEO. Having been at this position for less than a year, what are your impressions of…
You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed,…
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
See our Cookie Privacy Policy Here